February 24, 2017

Company’s CEO Acquires Shares in Oncopeptides

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the company’s CEO, Jakob Lindberg acquired 45,000 shares in Oncopeptides for a value of SE...
Read more
February 24, 2017

Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments

HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, t...
Read more
February 23, 2017

Final Results from NICHE Phase III trial presented at the International Stroke Conference

23 February 2017 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company with a pioneering navigated non-invasive brain stimulation system, tod...
Read more
February 23, 2017

Wilson Theraputics AB (publ) Year-end Report 2016

Feb 23, 2017 Good year-end data gives a promising start to 2017 October 1 – December 31, 2016 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK ...
Read more
February 22, 2017

Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2016 Results Presentation and Webcast

Nordic Nanovector ASA (OSE: NANO), a biopharmaceutical company focusing on the development and commercialisation of novel targeted therapeutics for haematological cancers, will...
Read more
February 22, 2017

Trading of Oncopeptides AB (publ) on Nasdaq Stockholm commences today

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.February 22, 2017 P...
Read more
February 21, 2017

GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

Paris, France, February 21, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and deve...
Read more
February 20, 2017

Orexo Completes Bond Buyback Program

Uppsala, Sweden – February 20, 2017 – Orexo AB (publ.) announces that it has successfully completed a limited bond buyback program and in total purchased Orexo corporate bonds ...
Read more
February 17, 2017

Publishing of Nexstim Plc 2016 Full Year Results

17 February 2017 Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company with a pioneering navigated non-invasive brain stimulation system, will announce its full year ...
Read more
February 17, 2017

2016 ANNUAL RESULTS

Solid cash position of €24.7 million and finalization of CARAT phase 2 clinical study Toulouse, France, Ann Arbor, United States, February 17 2017 – 6 pm CET – Cerenis The...
Read more